Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Expression of B7-H1, a costimulating glycoprotein in the B7 family, is normally restricted to macrophage-lineage cells, providing a potential costimulatory signal source for regulation of T cell activation. In contrast, aberrant expression of B7-H1 by tumor cells has been implicated in impairment of T cell function and survival, resulting in defective host antitumoral immunity. The relationship between tumor-associated B7-H1 and clinical cancer progression is unknown. Herein, we report B7-H1 expression by both renal cell carcinoma (RCC) tumors of the kidney and RCC tumor-infiltrating lymphocytes. In addition, our analysis of 196 clinical specimens reveals that patients harboring high intratumoral expression levels of B7-H1, contributed by tumor cells alone, lymphocytes alone, or tumor and/or lymphocytes combined, exhibit aggressive tumors and are at markedly increased risk of death from RCC. In fact, patients with high tumor and/or lymphocyte B7-H1 levels are 4.5 times more likely to die from their cancer than patients exhibiting low levels of B7-H1 expression (risk ratio 4.53; 95% confidence interval 1.94–10.56; P < 0.001.) Thus, our study suggests a previously undescribed mechanism whereby RCC may impair host immunity to foster tumor progression. B7-H1 may prove useful as a prognostic variable for RCC patients both pre- and posttreatment. In addition, B7-H1 may represent a promising target to facilitate more favorable responses in patients who require immunotherapy for treatment of advanced RCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Subsequent human studies have consistently shown that PD-L1 and PD-L2 expression not only increases in cancerous tissues but is also linked to poor disease prognosis in many cancer types (50)(51)(52)(53)(54)(55)(56).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [50]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Self-citationIwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,203
Dong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496
Self-citationPhan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575
The Heidelberg classification of renal cell tumours
Kovacs, G., Akhtar, M., Beckwith, B. J., Bugert, P., Cooper, C. S., Delahunt, B., Eble, J. N., Fleming, S., Ljungberg, B., Medeiros, L. J., et al. (1997) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199710)183:2<131::aid-path931>3.0.co;2-g · Cited by 1,354
FRANK, I., BLUTE, M. L., CHEVILLE, J. C., LOHSE, C. M., WEAVER, A. L., & ZINCKE, H. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)64153-5 · Cited by 1,175
Self-citationComparisons of Outcome and Prognostic Features Among Histologic Subtypes of Renal Cell Carcinoma
Cheville, J. C., Lohse, C. M., Zincke, H., Weaver, A. L., & Blute, M. L. (2003) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200305000-00005 · Cited by 1,087
Self-citationHodi, F. S., Mihm, M. C., Soiffer, R. J., Haluska, F. G., Butler, M., Seiden, M. V., Davis, T., Henry-Spires, R., MacRae, S., Willman, A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0830997100 · Cited by 1,006
CTLA-4: new insights into its biological function and use in tumor immunotherapy
Egen, J. G., Kuhns, M. S., & Allison, J. P. (2002) · Nature Immunology · doi:10.1038/ni0702-611 · Cited by 940
THE CHANGING NATURAL HISTORY OF RENAL CELL CARCINOMA
PANTUCK, A. J., ZISMAN, A., & BELLDEGRUN, A. S. (2001) · Journal of Urology · doi:10.1016/s0022-5347(05)65640-6 · Cited by 882
Research works printed but not linked: 13
- Strome, S.-E., Dong, H., Tamura, H., Voss, S.-G., Flies, D.-B., Tamada, K., Salomao, D., Cheville, J.-C, Hirano, F., Lin, W., et al. (2003) Cancer Res. 63, 6501–6505. [PubMed] [Google Scholar]
- Graham, S., Babayan, R.-K., Lamm, D.-L., Sawczuk, I., Ross, S.-D., Lavin, P.-T., Osband, M.-E. & Krane, R.-J. (1993) Semin. Urol. 11, 27–34. [PubMed] [Google Scholar]
- Krejci, K.-G., Markiewicz, M.-A. & Kwon, E.-D. (2003) J. Urol. 171, 870–876. [DOI] [PubMed] [Google Scholar]
- Nakano, O., Sato, M., Naito, Y., Suzuki, K., Orikasa, S., Aizawa, M., Suzuki, Y., Shintaku, I., Nagura, H. & Ohtani, H. (2001) Cancer Res. 61, 5132–5136. [PubMed] [Google Scholar]
- Storkel, S., Eble, J.-N., Adlakha, K., Amin, M., Blute, M.-L., Bostwick, D.-G., Darson, M., Delahunt, B. & Iczkowski, K. (1997) Cancer 80, 987–989. [DOI] [PubMed] [Google Scholar]
- Wintterle, S., Schreiner, B., Mitsdoerffer, M., Schneider, D., Chen, L., Meyermann, R., Weller, M. & Wiendl, H. (2003) Cancer Res. 63, 7462–7467. [PubMed] [Google Scholar]
- Uzzo, R.-G., Rayman, P., Kolenko, V., Clark, P.-E., Bloom, T., Ward, A.-M., Molto, L., Tannenbaum, C., Worford, L.-J, Bukowski, R.-M., et al. (1999) Clin. Cancer Res. 5, 1219–1229. [PubMed] [Google Scholar]
- Alexander, J.-P., Kudoh, S., Melsop, K.-A., Hamilton, T.-A., Edinger, M.-G., Tubbs, R.-R., Sica, D., Tuason, L., Klein, E., Bukowski, R., et al. (1993) Cancer. Res. 53, 1380–1387. [PubMed] [Google Scholar]
- Li, X., Liu, J., Park, J.-K., Hamilton, T.-A., Rayman, P., Klein, E., Edinger, M., Tubbs, R., Bukowski, R. & Finke, J. (1994) Cancer Res. 54, 5424–5429. [PubMed] [Google Scholar]
- Kudoh, S., Redovan, C., Rayman, P., Edinger, M., Tubbs, R.-R., Novick, A., Finke, J.-H. & Bukowski, R.-M. (1997) J. Immunol. 20, 479–487. [DOI] [PubMed] [Google Scholar]
- Motzer, R.-J. (2003) Crit. Rev. Oncol. Hematol. 46S, s33–s39. [DOI] [PubMed] [Google Scholar]
- Hofmockel, G., Tsatalpas, P., Muller, H., Dammrich, J., Poot, M., Maurer-Schultze, B., Muller-Hermelink, H.-K., Frohmuller, H.-G. & Bassukas, I.-D. (1995) Cancer 76, 296–306. [DOI] [PubMed] [Google Scholar]
- Shimazui, T., Oosterwijk, E., Akaza, H., Bringuier, P., Ruijter, E., van Berkel, H., Wakka, J.-O., van Bokhoven, A., Debruyne, F.-M. & Schalken, J.-A. (1998) Clin. Cancer Res. 4, 2419–2424. [PubMed] [Google Scholar]
Cited by
Items 501–600 of 796
Nicholas, S. E., Mathios, D., Ruzevick, J., Jackson, C. M., Yang, I., & Lim, M. K. (2013) · Brain Tumor Research and Treatment · doi:10.14791/btrt.2013.1.1.2 · Cited by 17
Ha, H., Bang, J., Nam, A., Park, J., Jin, M. H., Bang, Y., & Oh, D. (2018) · Cancer Research and Treatment · doi:10.4143/crt.2018.311 · Cited by 16
Qiu, Z., & Du, Y. (2021) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-20-568 · Cited by 16
Sun, X., Liu, L., Wan, T., Huang, Q., Chen, J., Luo, R., & Liu, J. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02716-6 · Cited by 17
A fully human monoclonal antibody targeting PD-L1 with potent anti-tumor activity
Luan, Y., Chai, D., Peng, J., Ma, S., Wang, M., Ma, H., Li, X., Fu, S., Pan, X., Wang, X., et al. (2016) · International Immunopharmacology · doi:10.1016/j.intimp.2015.12.039 · Cited by 16
Genito-urinary genomics and emerging biomarkers for immunomodulatory cancer treatment
Gevaert, T., Montironi, R., López-Beltrán, A., van Leenders, G., Allory, Y., Ridder, D. J. M. K. D., Claessens, F., Kockx, M. M., Akand, M., Joniau, S., et al. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.10.004 · Cited by 17
Frontiers and Opportunities: Highlights of the 2nd Annual Conference of the Chinese Antibody Society
Zhang, H., Deng, M., Lin, P., Liu, J., Liu, C., Strohl, W. R., Wang, S., & Ho, M. (2018) · Antibody Therapeutics · doi:10.1093/abt/tby009 · Cited by 17
Aristolochic Acid and Immunotherapy for Urothelial Carcinoma: Directions for unmet Needs
Yang, H., Yang, C., Wu, C., Wang, L.-J., & Lu, K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133162 · Cited by 16
Mischinger, J., Fröhlich, E., Mannweiler, S., Meindl, C., Absenger‐Novak, M., Hutterer, G. C., Seles, M., Augustin, H., Chromecki, T. F., Jesche, J., et al. (2019) · Editor-in-Chief s Voice List of Authors is an Important Element in a Scientific Publication · doi:10.5173/ceju.2018.1858 · Cited by 18
Effects of Decalcifying Agents of Variable Duration on PD-L1 Immunohistochemistry
Strickland, A. L., Blacketer, S., Molberg, K. H., Markantonis, J., & Lucas, E. (2019) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqz161 · Cited by 16
Kashani–Sabet, M. (2010) · Cancer · doi:10.1002/cncr.24909 · Cited by 16
Intellectual property issues of immune checkpoint inhibitors
Storz, U. (2015) · mAbs · doi:10.1080/19420862.2015.1107688 · Cited by 17
Hansen, F. J., David, P., Akram, M., Knoedler, S. A., Mittelstädt, A., Merkel, S., Podolska, M. J., Swierzy, I., Roßdeutsch, L., Klösch, B., et al. (2023) · Cancers · doi:10.3390/cancers15020363 · Cited by 19
Chan, J. Y., Choudhury, Y., & Tan, M. (2015) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2015.1032261 · Cited by 17
Jung, S. G., Choi, K. U., Lee, S. D., Lee, Z. Z., & Chung, M. K. (2011) · Korean journal of urology · doi:10.4111/kju.2011.52.2.90 · Cited by 15
MicroRNAs as Immunotherapy Targets for Treating Gastroenterological Cancers
Yang, Y., Alderman, C., Sehlaoui, A., Xiao, Y., & Wang, W. (2018) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2018/9740357 · Cited by 15
Liu, T., Sui, J., Zhang, Y., Zhang, X., Wu, W., Yang, S., Xu, S., Hong, W., Peng, H., Yin, L., et al. (2018) · Oncology Reports · doi:10.3892/or.2018.6540 · Cited by 17
Immune checkpoint inhibition for the treatment of renal cell carcinoma
Stühler, V., Maas, J. M., Rausch, S., Stenzl, A., & Bedke, J. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1677601 · Cited by 17
Hong, M. E., Kim, J. W., Kim, M. K., Chung, B. W., & Ahn, S. K. (2020) · Journal of Cancer · doi:10.7150/jca.50441 · Cited by 15
PD-L1 expression in bladder cancer: Which scoring algorithm in what tissue?
Schulz, G. B., Todorova, R., Braunschweig, T. A., Rodler, S., Volz, Y., Eismann, L., Pfitzinger, P. L., Jokisch, F., Büchner, A., Stief, C. G., et al. (2021) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2021.06.001 · Cited by 15
Hua, X., Chu, H., Wang, C., Shi, X., Wang, A., & Zhang, Z. (2021) · Oncology Reports · doi:10.3892/or.2021.8166 · Cited by 16
Prognostic value of programed death ligand 1 in patients with solid tumors: A meta-analysis
Jin, Y., Zhao, J., Shi, X., & Yu, X. (2015) · Journal of Cancer Research and Therapeutics · doi:10.4103/0973-1482.163837 · Cited by 14
Determination of PD‐L1 expression in effusions from mesothelioma by immuno‐cytochemical staining
Mansour, M. S. I., Seidal, T., Mager, U., Baigi, A., Dobra, K., & Dejmek, A. (2017) · Cancer Cytopathology · doi:10.1002/cncy.21917 · Cited by 14
CD8+ T Cells in Immunotherapy, Radiotherapy, and Chemotherapy
Wang, W., Green, M. D., Liu, J. R., Lawrence, T. S., & Zou, W. (2017) · Springer eBooks · doi:10.1007/978-3-319-62431-0_3 · Cited by 21
Cancer Clonal Theory, Immune Escape, and Their Evolving Roles in Cancer Multi-Agent Therapeutics
Messerschmidt, J. L., Bhattacharya, P., & Messerschmidt, G. L. (2017) · Current Oncology Reports · doi:10.1007/s11912-017-0625-2 · Cited by 16
Ambrosius, L. A., Dhawan, D., Ramos, J. A., Ruple, A., Knapp, D. W., & Childress, M. O. (2018) · American Journal of Veterinary Research · doi:10.2460/ajvr.79.6.643 · Cited by 14
Programmed Death Ligand 1; An Immunotarget for Renal Cell Carcinoma
Chandrasekaran, D., Sundaram, S., Kadhiresan, N., & Padmavathi, R. (2019) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2019.20.10.2951 · Cited by 15
Ortíz-Sánchez, E., Chávez-Olmos, P., Piña‐Sánchez, P., Salcedo, M., & Garrido, E. (2007) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-00009577-200705000-00004 · Cited by 14
RORγT agonists as immune modulators in anticancer therapy.
Pastwińska, J., Karwaciak, I., Karaś, K., Bachorz, R. A., & Ratajewski, M. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.189021 · Cited by 16
Michael, A., Relph, K., Annels, N. E., & Pandha, H. (2013) · Expert Review of Vaccines · doi:10.1586/erv.13.27 · Cited by 17
Efficacy and safety profile of nivolumab for Japanese patients with metastatic renal cell cancer
Fujiwara, R., Inamura, K., Yuasa, T., Numao, N., Yamamoto, S., Masuda, H., Kawauchi, A., Takeuchi, K., & Yonese, J. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01542-7 · Cited by 13
Molecular mechanisms of breast cancer chemoresistance by immune checkpoints
Dastmalchi, N., Safaralizadeh, R., Baghbanzadeh, A., Hajiasgharzadeh, K., Asl, E. R., Amini, M. A., & Baradaran, B. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118604 · Cited by 14
CD4, CD20 and PD-L1 as Markers of Recurrence in Non-Muscle-Invasive Bladder Cancer
Semeniuk-Wojtaś, A., Modzelewska, M., Poddębniak-Strama, K., Kołaczyńska, S., Lubas, A., Górnicka, B., Jakieła, A., & Stec, R. (2023) · Cancers · doi:10.3390/cancers15235529 · Cited by 17
Lalami, Y., & Awada, A. H. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.01.001 · Cited by 15
Tannir, N. M., Hammers, H. J., & Amin, A. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1423960 · Cited by 15
Review of the recent clinical trials for PD-1/PD-L1 based lung cancer immunotherapy
Behrouzieh, S., Sheida, F., & Rezaei, N. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1996230 · Cited by 14
Durvalumab: an investigational agent for unresectable hepatocellular carcinoma
Maestri, M., Pallozzi, M., Santopaolo, F., Cerrito, L., Pompili, M., Gasbarrini, A., & Ponziani, F. R. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2033208 · Cited by 13
More Support for the Judicious Use of High-Dose Interleukin-2 in Patients With Advanced Melanoma
McDermott, D. F., & Atkins, M. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.9552 · Cited by 13
Bansal, A., Lavoie, R. R., Lucien, F., Kethamreddy, M., Wootla, B., Dong, H., Park, S. S., & Pandey, M. K. (2024) · Scientific Reports · doi:10.1038/s41598-024-70385-8 · Cited by 13
Self-citationDendritic Cell Cancer Vaccines: From the Bench to the Bedside
Katz, T., Avivi, I. M., Benyamini, N., Rosenblatt, J. M., & Avigan, D. (2014) · Rambam Maimonides Medical Journal · doi:10.5041/rmmj.10158 · Cited by 12
Immunologics and Chemotherapeutics for Renal Cell Carcinoma
Diamond, E., Riches, J. C., Faltas, B. M., Tagawa, S. T., & Nanus, D. M. (2014) · Seminars in Interventional Radiology · doi:10.1055/s-0033-1363848 · Cited by 12
Zengin, M. (2019) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2019.05.007 · Cited by 12
Predictive and prognostic biomarkers in urological tumours
Cimadamore, A., Franzese, C., Loreto, C. D., Blanca, A., López-Beltrán, A., Crestani, A., Giannarini, G., Tan, P. H., Carneiro, B. A., El‐Deiry, W. S., et al. (2023) · Pathology · doi:10.1016/j.pathol.2023.10.016 · Cited by 12
Inhibitors of B7–CD28 Costimulation in Urologic Malignancies
Thompson, R. H., Kwon, E. D., & Allison, J. P. (2008) · Immunotherapy · doi:10.2217/1750743x.1.1.129 · Cited by 15
Self-citationBrown, C. N., Atwood, D. J., Pokhrel, D., Ravichandran, K., Holditch, S. J., Saxena, S., Miyazaki, M., Nemenoff, R. A., Weiser‐Evans, M. C. M., Ljubanović, D. G., et al. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109605 · Cited by 14
Kiyozawa, D., Takamatsu, D., Kohashi, K., Kinoshita, F., Ishihara, S., Toda, Y., Eto, M., & Oda, Y. (2020) · Human Pathology · doi:10.1016/j.humpath.2020.04.003 · Cited by 14
Increased soluble programed cell death-ligand 1 is associated with acute coronary syndrome
Fujisue, K., Yamamoto, E., Sueta, D., Takae, M., Nishihara, T., Komorita, T., Usuku, H., Yamanaga, K., Ito, M., Hoshiyama, T., et al. (2021) · International Journal of Cardiology · doi:10.1016/j.ijcard.2021.11.060 · Cited by 12
Takamaru, N., Fukuda, N., Akita, K., Kudoh, K., & Miyamoto, Y. (2022) · Oncology Letters · doi:10.3892/ol.2022.13195 · Cited by 13
Jeong, S. U., Hwang, H. S., Park, J.-M., Yoon, S. Y., Shin, S., Go, H., Lee, J., Jeong, G., & Cho, Y. M. (2022) · Cancer Research and Treatment · doi:10.4143/crt.2021.1526 · Cited by 12
Costimulation in Lymphomas and Cancers
Mir, M. A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-802585-7.00005-4 · Cited by 13
Immunotherapy for Prostate Cancer: An Emerging Treatment Modality
Drake, C. G. (2010) · Urologic Clinics of North America · doi:10.1016/j.ucl.2009.11.001 · Cited by 13
Zheng, T., Yu, X., Yu, C., Xu, W., Fan, Z., Zhou, Y., Li, C., Wan, J., Jin, C., Jin, X., et al. (2025) · Biomarker Research · doi:10.1186/s40364-025-00883-y · Cited by 11
Lee, S. M., Hamid, O., Jotte, R. M., Zakharia, Y., Medina, T. M., Gillespie-Twardy, A. L., Mehmi, I., Chandra, S., Watson, G. T., Ward, P. J., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1478 · Cited by 11
B7molecule mRNA expression in colorectal carcinoma
Xiao, J., Bai, P., Lai, B.-C., Li, L., Zhu, J., & Wang, Y.-L. (2005) · World Journal of Gastroenterology · doi:10.3748/wjg.v11.i36.5655 · Cited by 11
Rrapaj, E., Giacometti, L., Spina, P., Salvo, M., Baselli, G., Veggiani, C., Rena, O., Trisolini, E., & Boldorini, R. L. (2020) · Pathology · doi:10.1016/j.pathol.2020.09.018 · Cited by 11
Dai, D., Guo, Y., Shui, Y., Li, J., Jiang, B., & Wei, Q. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.775562 · Cited by 11
Immunochemotherapy benefits in gastric cancer patients stratified by programmed death-1 ligand-1
Hsu, J., Hsu, C., Le, P., Chen, T., Chou, W., Lin, C., & Yeh, T. (2016) · Journal of Surgical Research · doi:10.1016/j.jss.2016.11.058 · Cited by 12
Kumar, B., Ghosh, A., Datta, C., & Pal, D. K. (2019) · Therapeutic Advances in Urology · doi:10.1177/1756287219868859 · Cited by 13
PD-L1 expression is an unfavourable prognostic indicator in Asian renal cell carcinomas
Yeong, J. P.-S., Zhao, Z., Lim, J. C. T., Li, H., Thike, A. A., Koh, V. C. Y., Teh, B. T., Kanesvaran, R., Toh, C., Tan, P. H., et al. (2020) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2019-206092 · Cited by 12
Mazzaschi, G., Quaini, F., Bersanelli, M., & Buti, S. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103293 · Cited by 11
Hong, B., Cai, L., Wang, J., Liu, S., Zhou, J., Ma, K., Zhang, J., Zhou, B., Peng, X., Zhang, N., et al. (2018) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2018.11.001 · Cited by 10
Grellier, E., Lécolle, K., Rogée, S., Couturier, C., D'Halluin, J.-C., Hong, S. S., Fender, P., Boulanger, P. A., Quesnel, B., & Colin, M. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-105 · Cited by 10
Tripathi, A., Kaymakcalan, M. D., LeBoeuf, N. R., & Harshman, L. C. (2016) · Current Opinion in Urology · doi:10.1097/mou.0000000000000332 · Cited by 10
Prognostic and Predictive Factors for Renal Cell Carcinoma
Suárez, C., Campayo, M., Bastús, R., del Castillo, S. S. F., Etxanitz, O., Guix, M., Sala, N., & Gallardo, E. (2018) · Targeted Oncology · doi:10.1007/s11523-018-0557-2 · Cited by 11
BIN1 in cancer: biomarker and therapeutic target
Chen, S., Cao, J., Li, K., Wan, S., & Li, Y. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04673-7 · Cited by 11
Tomiyama, N., Tasaki, Y., Hamamoto, S., Sugiyama, Y., Naiki, T., Etani, T., Taguchi, K., Matsuyama, N., Sue, Y., Mimura, Y., et al. (2023) · International Journal of Urology · doi:10.1111/iju.15198 · Cited by 10
Ding, R., Liu, S., Wang, S., Chen, H., Wang, F., Xu, Q., Zhu, L., Dong, X., Gu, Y., Zhang, X., et al. (2021) · Theranostics · doi:10.7150/thno.55075 · Cited by 10
Gupta, A., Gupta, S., Das, U. B., & Sinha, S. (2022) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.2c00129 · Cited by 10
Jamil, M. L., Deebajah, M., Sood, A., Robinson, K., Rao, K., Sana, S., & Alanee, S. R. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-028287 · Cited by 10
Iacovelli, R., Ciccarese, C., Maruzzo, M., Atzori, F., Galli, L., Scagliarini, S., Massari, F., Verzoni, E., Cannella, A., Maratta, M. G., et al. (2022) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2022.06.006 · Cited by 9
Immunotherapy for Prostate Cancer Enters Its Golden Age
Boikos, S. A., & Antonarakis, E. S. (2012) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s7475 · Cited by 9
Immunotherapy in Non-Small-Cell Lung Cancer: A Bridge Between Research and Clinical Practice
Passiglia, F., Commendatore, O., Vitali, M., & Conca, R. (2018) · Future Oncology · doi:10.2217/fon-2018-0098 · Cited by 10
Tooyserkani, R., Rasaee, M. J., Bandehpour, M., & Löwik, D. W. P. M. (2021) · Journal of drug targeting · doi:10.1080/1061186x.2021.1879087 · Cited by 10
Harnessing the PD-1 Pathway in Renal Cell Carcinoma: Current Evidence and Future Directions
Tripathi, A., Drake, C. G., & Harshman, L. C. (2014) · BioDrugs · doi:10.1007/s40259-014-0111-4 · Cited by 10
Tiemann, M., Samoilova, V. E., Atiakshin, D., & Buchwalow, I. (2020) · BMC Research Notes · doi:10.1186/s13104-020-04975-w · Cited by 9
Les récidives des tumeurs des voies aérodigestives supérieures
Martin, L., Zoubir, M., & Tourneau, C. L. (2014) · Bulletin du Cancer · doi:10.1684/bdc.2014.1970 · Cited by 9
Chrabańska, M., Szweda-Gandor, N., Rynkiewicz, M., Hraboš, D., & Drozdzowska, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073916 · Cited by 8
Potential Mechanisms for Immunotherapy Resistance in Adult Soft-Tissue Sarcoma
Kret, Z. S., Sweder, R. J., Pollock, R. E., & Tinoco, G. (2025) · Targeted Oncology · doi:10.1007/s11523-025-01145-5 · Cited by 8
Kedmi, M., Avigdor, A., & Nagler, A. (2014) · Acta Haematologica · doi:10.1159/000362151 · Cited by 8
Checkpoint Blockade - a New Treatment Paradigm in Renal Cell Carcinoma
Grünwald, V. (2016) · Oncology Research and Treatment · doi:10.1159/000446718 · Cited by 9
Xiao, W., Xu, F., Zhang, X., Zhou, S., Zhang, H., Dai, B., Zhu, Y., Shi, G., Shen, Y.-J., Zhu, Y., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00879 · Cited by 9
Tumor immune microenvironment is associated with the growth of intracranial germinomas
Nishimoto, M., Ohara, K., Kamamoto, D., Tamura, R., Miwa, T., Yoshida, K., & Sasaki, H. (2019) · Journal of Neuro-Oncology · doi:10.1007/s11060-019-03355-0 · Cited by 8
An update on current management of advanced renal cell cancer, biomarkers, and future directions
Zhi, W. I., & Kim, J. (2014) · journal of cancer therapeutics and research · doi:10.7243/2049-7962-3-8 · Cited by 11
Prognostic biomarkers in renal cell carcinoma
Jiang, Z. (2007) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.7.3.293 · Cited by 8
Quesnel, B. (2006) · Expert Review of Vaccines · doi:10.1586/14760584.5.6.773 · Cited by 8
B7-H1(PD-L1) confers chemoresistance through ERK and p38 MAPK pathway in tumor cellsPreprint
Wu, X., Li, Y., Liu, X., Cao, S., Harrington, S. M., Chen, C., Mansfiled, A. S., Dronca, R. S., Park, S. S., Yan, Y., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/308601 · Cited by 8
Self-citationFeng, S., Shen, Y., Zhang, H., Liu, W., Feng, W., Chen, X., Zhang, L., Chen, J., Lu, M., Xue, X., et al. (2025) · Molecular Medicine · doi:10.1186/s10020-025-01114-8 · Cited by 7
Safaei, H. R., Rostamzadeh, A., Rahmani, O., Mohammadi, M., Ghaderi, O., Yahaghi, H., & Ahmadi, K. (2015) · Tumor Biology · doi:10.1007/s13277-015-4652-z · Cited by 7
RetractedFang, X., Liu, X., Lü, L., & Liu, G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.728181 · Cited by 9
McNamara, M. A., Zhang, T., Harrison, M. R., & George, D. J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00079-7 · Cited by 7
Yang, S., Son, H. Y., Park, M., Rho, H. W., Lee, H., & Huh, Y. (2023) · Cancer Nanotechnology · doi:10.1186/s12645-023-00171-0 · Cited by 7
Wang, Q., Zhao, Y., Chen, Y., Chen, Y., Song, X., Zhang, L., He, Q., Ye, B., Wu, L., Huang, X., et al. (2023) · Head & Neck · doi:10.1002/hed.27329 · Cited by 7
T-cell checkpoint inhibitors in metastatic renal cell carcinoma
Grünwald, V. (2015) · Current Opinion in Urology · doi:10.1097/mou.0000000000000199 · Cited by 8
Saleh, R., Scott, J. L., Meti, N., Perlon, D., Fazelzad, R., Ocaña, A., & Amir, E. (2022) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-022-00576-4 · Cited by 7
Timeline: a decade of advances in immunotherapy
Pardoll, D. M. (2011) · Nature Medicine · doi:10.1038/nm0311-296 · Cited by 7
Haque, S., Yellu, M., Randhawa, J. S., & Sadraei, N. H. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s119537 · Cited by 9
Malesa, A., Nowak, J., Skórka, K., Karp, M., & Giannopoulos, K. (2018) · Acta Haematologica Polonica · doi:10.2478/ahp-2018-0025 · Cited by 7
Wang, C., Huang, K., Chang, H., Tseng, C., Lai, C., Lan, J., Liu, T., Huang, C., & Lin, M. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.14216 · Cited by 7
Ebner, D. K., Tinganelli, W., Helm, A., Bisio, A., Simoniello, P., Natale, F., Yamada, S., Kamada, T., Shimokawa, T., & Durante, M. (2017) · Translational Cancer Research · doi:10.21037/tcr.2017.06.01 · Cited by 7
The Many Sounds of T Lymphocyte Silence
Melero, I., Arina, A., & Chen, L. (2005) · Immunologic Research · doi:10.1385/ir:33:2:135 · Cited by 7
Self-citation
Metadata
- Authors
- Thompson, R. H., Gillett, M. D., Cheville, J. C., Lohse, C. M., Dong, H., Webster, W. S., Krejci, K. G., Lobo, J. R., Sengupta, S., Chen, L., Zincke, H., Blute, M. L., Strome, S. E., Leibovich, B. C., & Kwon, E. D.
- Affiliations
- Mayo Clinic (US)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2004-11-29
- Volume
- 101
- Issue
- 49
- Pages
- 17174-17179
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC534606
- OpenAlex
- W4230861071
- Cited by
- 776
- References
- 48
- Citations by year
- 2026: 7 · 2025: 14 · 2024: 15 · 2023: 29 · 2022: 32 · 2021: 42 · 2020: 51 · 2019: 60 · 2018: 57 · 2017: 76 · 2016: 65 · 2015: 69 · 2014: 57 · 2013: 29 · 2012: 28
- FWCI
- 9.14
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- PD-L1, renal cell carcinoma, tumor-infiltrating lymphocytes, tumor progression, prognostic factors, tumor immune evasion, T cell costimulation, immunotherapy targets, cancer mortality
- MeSH terms
- Carcinoma, Renal Cell, Follow-Up Studies, Humans, Immunity, Immunohistochemistry, Membrane Glycoproteins, Neoplasm Proteins, Peptides, Prognosis, Antigens, CD, Odds Ratio, Survival Analysis, Lymphocytes, Tumor-Infiltrating, B7-1 Antigen, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.